Poolbeg Pharma’s (POLB) House Stock Rating Reiterated at Shore Capital

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating restated by investment analysts at Shore Capital in a report issued on Wednesday, Marketbeat.com reports.

Poolbeg Pharma Stock Performance

Shares of POLB stock traded up GBX 0.29 on Wednesday, reaching GBX 4.34. 3,351,753 shares of the company were exchanged, compared to its average volume of 2,306,615. The company has a market cap of £30.26 million, a price-to-earnings ratio of -3.81 and a beta of 2.11. The business has a 50-day moving average price of GBX 4.09 and a 200 day moving average price of GBX 3.68. Poolbeg Pharma has a 1 year low of GBX 2.25 and a 1 year high of GBX 5.50.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.